Intersect ENT received CMS approval of a revised coding application for its Propel sinus implant, according to a Jan. 19 news release. Propel previously shared a billing code with Intersect ENT’s ...

Maxillary sinus augmentation remains a cornerstone intervention for addressing insufficient bone height in the posterior maxilla prior to dental implant placement. Techniques such as the lateral ...

Lower health care utilization was shown in patients with chronic rhinosinusitis, with and without nasal polyps, who had steroid-eluting implants vs those who did not in the 18 months following ...

How do the long-term results of short implants compare with those of long implants placed after maxillary sinus augmentation? To get a clear look at the risks and benefits of each, researchers ...

Intersect ENT is launching its Sinuva Sinus Implant, a new approach to treating nasal polyp disease in adult patients who have had previous sinus surgery. The Menlo Park, CA-based company said nearly ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...

A synthetic biphasic calcium phosphate material proved as reliable after a year as deproteinized cow bone for sinus augmentation in a clinical implant trial reported online May 11 in Clinical Implant ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...

Sinus lift surgery is also known as sinus augmentation – a dental procedure involving adding bone to the upper jaw’s posterior area. This procedure is often deemed necessary when a patient has ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...